Jiuzhou Pharma(603456.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Jiuzhou Pharma
603456.SH
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and scientific research institutions.
2.805 T
603456.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking24/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.37%B
    • Profit Margin12.49%B
    • Gross Margin36.37%C
  • Growth ScoreC
    • Revenue YoY0.85%C
    • Net Profit YoY5.23%C
    • Total Assets YoY-4.01%D
    • Net Assets YoY0.98%C
  • Cash ScoreB
    • Cash Flow Margin256.85%A
    • OCF YoY0.85%C
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreA
    • Gearing Ratio15.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

    Zhitong·
    SZ
    301230
    -1.75%
    SZ
    300347
    -1.36%
    HK
    03347
    -2.39%
    Zhitong·
    SZ
    301230
    -1.75%
    SZ
    300347
    -1.36%
    HK
    03347
    -2.39%

    Jiuzhou Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 748 million yuan, a year-on-year increase of 18.51%

    Zhitong·
    SH
    603456
    -1.21%
    Zhitong·
    SH
    603456
    -1.21%

    CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

    Zhitong·
    SZ
    000739
    +2.80%
    SH
    603456
    -1.21%
    SH
    603127
    +1.04%
    Zhitong·
    SZ
    000739
    +2.80%
    SH
    603456
    -1.21%
    SH
    603127
    +1.04%

    Jiuzhou Pharma's subsidiary Ruibo Suzhou passes on-site inspection by the U.S. FDA

    Zhitong·
    SH
    603456
    -1.21%
    Zhitong·
    SH
    603456
    -1.21%

    Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points

    Zhitong·
    SH
    603456
    -1.21%
    Zhitong·
    SH
    603456
    -1.21%
    © 2026 Longbridge｜Disclaimer